Dr Reddy’s to manufacture Baricitinib drug for Covid treatment
The drug baricitinib has received restricted emergency use approval from the CDSCO, for use in combination with Remdesivir for COVID-19 treatment.
By IANS| Updated: 12th May 2021 11:26 am IST
entered into a royalty-free, non-exclusive voluntary licensing agreement for the same. (Photo: Company Logo)
Hyderabad: Pharma major Dr. Reddy’s Laboratories Ltd on Wednesday announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialization of Baricitinib in India.
The drug baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with Remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).